Other pathways in skeletal muscle that have been targeted in pre-clinical mouse models and show promise in treating DMD include hypertrophy/growth (PI3K/mTOR/AKT) [47] and cholesterol/metabolism [48] pathways. The gene discussed is MTOR; the disease is Duchenne muscular dystrophy.